Igraine Plc ARCADIA trial final report date announced

 
TIDMKING 
 
18 August 2021 
 
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO 
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION 
(EU) NO. 596/2014, AS AMENDED ("MAR"). ON THE PUBLICATION OF THIS 
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE ("RIS"), THIS INSIDE 
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. 
 
                                  Igraine plc 
 
                         ("Igraine" or the "Company") 
 
                   ARCADIA trial final report date announced 
 
Igraine plc ("the Company") notes the announcement on August 17, 2021 by 
Excalibur Medicines Limited, a subsidiary of Excalibur Healthcare Services Ltd 
- www.excaliburhealth.co.uk/news. Igraine is pleased to advise that the 
Clinical Team will report on the ARCADIA trial on September 6, 2021. 
 
Excalibur Medicines Ltd ("EML") has secured exclusive rights to and owns the 
patents on a drug, AZD1656, which is being developed as a potential therapeutic 
for people with diabetes suffering from COVID-19. The ARCADIA trial which took 
place across 31 sites was completed in July this year. 
 
The research project was arranged and structured by Professor Sir Chris Evans, 
Chairman and CEO of Excalibur Healthcare Services, through its subsidiary, 
Excalibur Medicines Ltd. Sir Chris worked closely with Professor John Martin 
and his team at St George Street, a UK-based biomedical research charity, which 
secured the initial project and permission to run the trial from AstraZeneca. 
 
Igraine plc secured a 2% Equity Interest in, Excalibur Medicines Ltd ("EML"), 
consistent with the terms of the co-investment agreement entered with Excalibur 
Healthcare Services. 
 
The Directors of the Company, who have issued this RIS announcement after due 
and careful enquiry, accept responsibility for its content. 
 
Enquiries 
 
Company: 
 
Martin Walton (Executive Director) 
Steve Winfield (Executive Director) 
info@igraineplc.com 
 
Office Line: +44 (0) 20 3778 0755 
 
AQSE Growth Market Corporate Adviser 
 
Peterhouse Capital Limited 
Guy Miller / Mark Anwyl 
Tel: +44 (0) 207 469 0930 
 
Media inquiries: 
Ramsay Smith, Media House International 
ramsay@mediahouse.co.uk: +44 (0) 7788414856 
 
 
 
END

(END) Dow Jones Newswires

August 18, 2021 02:00 ET (06:00 GMT)

Igraine (AQSE:KING)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024